Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender youth. Methods: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III. Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.

Original languageEnglish (US)
Pages (from-to)544-546
Number of pages3
JournalJournal of Adolescent Health
Volume64
Issue number4
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Feminization
Transgender Persons
Androgens
Gonadotropin-Releasing Hormone
Puberty
Insurance
Estrogens
Breast
Pediatrics
bicalutamide
Gender Dysphoria

Keywords

  • Bicalutamide
  • Gender dysphoria
  • Puberty blocker
  • Transgender care

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health
  • Psychiatry and Mental health

Cite this

@article{e61e09c3d61246de9d82f61c51a692fb,
title = "Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents",
abstract = "Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender youth. Methods: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6{\%} had breast development within 6 months, the majority being ≥ Tanner stage III. Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.",
keywords = "Bicalutamide, Gender dysphoria, Puberty blocker, Transgender care",
author = "Anna Neyman and John Fuqua and Erica Eugster",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.jadohealth.2018.10.296",
language = "English (US)",
volume = "64",
pages = "544--546",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents

AU - Neyman, Anna

AU - Fuqua, John

AU - Eugster, Erica

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender youth. Methods: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III. Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.

AB - Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender youth. Methods: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III. Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.

KW - Bicalutamide

KW - Gender dysphoria

KW - Puberty blocker

KW - Transgender care

UR - http://www.scopus.com/inward/record.url?scp=85059401753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059401753&partnerID=8YFLogxK

U2 - 10.1016/j.jadohealth.2018.10.296

DO - 10.1016/j.jadohealth.2018.10.296

M3 - Article

VL - 64

SP - 544

EP - 546

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 4

ER -